{
 "company": "iX Biopharma Ltd.",
 "ticker": "SGX:42C",
 "source_page": "https://smidresearch.com/companies/ix-biopharma/",
 "information_cutoff": "22 September 2026",
 "licence": "Public evidence-library figures as filed by the issuer and recomputed by SMID Research; cite the page and its information cut-off. No rating, fair value, price target or recommendation is included. Not investment advice.",
 "tables": [
  {
   "index": 1,
   "section": "FY2026 record",
   "caption": "Reported group results, year ended 30 June. S$’000. Source: unaudited FY2026 interim statements.",
   "headers": [
    "Line",
    "FY2026",
    "FY2025"
   ],
   "rows": [
    [
     "Revenue",
     "6,853",
     "7,767"
    ],
    [
     "Gross profit",
     "2,434",
     "2,040"
    ],
    [
     "Loss for the year",
     "(7,993)",
     "(10,141)"
    ],
    [
     "Net cash used in operating activities",
     "(7,506)",
     "(3,758)"
    ],
    [
     "Cash and cash equivalents on the balance sheet",
     "14,735",
     "866"
    ],
    [
     "Net assets",
     "15,396",
     "365"
    ]
   ]
  },
  {
   "index": 2,
   "section": "Share price record",
   "caption": "Every retained move: four windows. Residual means the move after the Straits Times Index control only; no same-session peer control was frozen.",
   "headers": [
    "#",
    "Session",
    "42C",
    "STI",
    "Peers",
    "Left over",
    "Control result",
    "What the evidence supports"
   ],
   "rows": [
    [
     "1",
     "12 Sep to 27 Oct 2025",
     "+535.00%",
     "+2.21%",
     "n/a",
     "+532.79%",
     "Residual",
     "The price rose from S$0.020 to S$0.127 while the Straits Times Index rose 2.21%. No issuer filing inside this window is used as a cause. The S$6.7 million placement was announced on 28 October 2025, after this window ended. Peer control unavailable: no same-session listed peer set was frozen for this exhibit."
    ],
    [
     "2",
     "2 Feb to 20 Feb 2026",
     "+20.69%",
     "+2.56%",
     "n/a",
     "+18.13%",
     "Residual",
     "The price rose from S$0.174 to S$0.210 while the Straits Times Index rose 2.56%. This window is retained because the residual is large. No filing inside the window is treated as the cause. Peer control unavailable: no same-session listed peer set was frozen for this exhibit."
    ],
    [
     "3",
     "31 Mar to 16 Apr 2026",
     "+120.51%",
     "+2.50%",
     "n/a",
     "+118.01%",
     "Residual",
     "The price rose from S$0.195 to S$0.430 while the Straits Times Index rose 2.50%. On 16 April 2026 the company announced a proposed placement at that day's volume-weighted average price of S$0.4215. The announcement falls on the last day of the window. It is not evidence that the earlier sessions were caused by the filing. Peer control unavailable: no same-session listed peer set was frozen for this exhibit."
    ],
    [
     "4",
     "18 Aug to 25 Aug 2026",
     "-12.37%",
     "+0.60%",
     "n/a",
     "-12.97%",
     "Residual",
     "The price fell from S$0.485 to S$0.425 while the Straits Times Index rose 0.60%. The unaudited FY2026 results are dated 21 August 2026 and are shown beside this window. The chart does not treat that filing as the cause of the move. Peer control unavailable: no same-session listed peer set was frozen for this exhibit."
    ]
   ]
  }
 ]
}